COMP <GO>
TWST vs KRYS // RSI-14 & 200D SMA MOMENTUM
Twist Bioscience Corporation (NASDAQ) VS. Krystal Biotech Inc. (NASDAQ) • 15-METRIC TALLY: TWST 3
— KRYS 7
▲ RSI-14 & 200D SMA MOMENTUM LEADER: KRYS
LAST: $129.04 (-15.54%) • MKT CAP: $10.13B
rsi-technicals
48.4
LAST: $295.90 (-10.95%) • MKT CAP: $9.84B
rsi-technicals
53.8
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TWST VS. KRYS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TWST | KRYS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 94.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.70% | 16.50% | -28.20 | KRYS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 53.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.66% | 1.97% | -2.63 | KRYS | /fcf-yield <GO> |
| Operating Margin | -4.20% | 41.50% | -45.70 | KRYS | /operating-margins <GO> |
| Net Profit Margin | -2.40% | 52.60% | -55.00 | KRYS | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 33.90% | -17.40 | KRYS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 26.00 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | KRYS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 48.4 | 53.8 | -5.40 | KRYS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.91 | +0.07 | TWST | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 39.4x | -18.40 | TWST | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.13B | $9.84B | $294.1M | TWST | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TWST REV | KRYS REV | TWST GROSS % | KRYS GROSS % | TWST FCF | KRYS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $381.5M | $389.1M | — | — | -$75.6M | $188.9M |
| FY 2024 | $618.3M | $290.5M | — | — | -$69.2M | $119.2M |
| FY 2023 | $608.0M | $50.7M | — | — | -$142.5M | -$91.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TWST // BETA 0.98
KRYS // BETA 0.91